Novel agents for the treatment of lymphomas during pregnancy: A comprehensive literature review

Luttwak, Efrat; Gurevich-Shapiro, Anna; Azem, Foad; Lishner, Michael; Klieger, Chagit; Herishanu, Yair; Perry, Chava; Avivi, Irit

doi:10.1016/j.blre.2021.100831

Cited by 5 publications

(6 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lenalidomide, because of its structural similarity with Thalidomide and because of the undisputable teratogenic effects of the parent drug, is absolutely contraindicated during pregnancy. 31 Bruton's tyrosine kinase inhibitors such as Ibrutinib and Acalabrutinib are also contraindicated during pregnancy. Studies in rats have shown that Ibrutinib induces fetal cardiac and blood vessel malformations 41 ; furthermore, by causing platelet dysfunction, the use of Ibrutinib in pregnancy carries an increased risk of bleeding.…”

Section: What Are the Fetal Toxicities Of The Novel Agents (Including...mentioning

confidence: 99%

“…Polatuzumab Vedotin is also not considered safe in pregnancy, as animal studies have demonstrated embryofetal mortality and structural abnormalities. 31 Among the immune checkpoint inhibitors, the anti PD-1 Nivolumab and Pembrolizumab are currently approved for the treatment of patients with relapsed/refractory HL. Treatment with anti-PD1 may interfere with maternal-fetal tolerance and increase the risk of pregnancy interruption, 32 showing increased incidence of miscarriage, stillbirth, preterm delivery, low-birthweight, and newborns mortality.…”

Section: What Are the Fetal Toxicities Of The Novel Agents (Including...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…Thus, the use of BV in pregnancy is not currently recommended. Polatuzumab Vedotin is also not considered safe in pregnancy, as animal studies have demonstrated embryofetal mortality and structural abnormalities 31 …”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Lymphomas in pregnancy

Pirosa

Peccatori

2023

Hematological Oncology

View full text Add to dashboard Cite

Lymphoma in pregnancy is an uncommon occurrence. This diagnosis is challenging, and a multidisciplinary team of specialists in obstetrics, anesthesiology, neonatology, hematology psychology should participate in the management of this condition. The choice of treatment regimen depends on the histotype and the gestational age. In Hodgkin lymphoma, ABVD is safe if administered after the thirteenth week of pregnancy. In indolent non-Hodgkin Lymphomas (NHL) a watchful waiting approach is reasonable; in case of aggressive NHLs, if the diagnosis occurs in the first gestational weeks, a termination of the pregnancy might be considered or if it occurs after the thirteenth week of pregnancy, a standard R-CHOP regimen is safe. Regarding new anti-lymphoma drugs, available data on the potential fetotoxicity of these agents are limited. Data collection regarding the use of new drugs in pregnant patients is mandatory in order to learn more about their safety and facilitating clinical decision making in this setting of patients.

show abstract

Section: What Are the Fetal Toxicities Of The Novel Agents (Including...mentioning

confidence: 99%

Section: What Are the Fetal Toxicities Of The Novel Agents (Including...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Lymphomas in pregnancy

Pirosa

Peccatori

2023

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…В единичных иссле дованиях также продемонстрированы высокие пока затели эмбрио и фетотоксического действия. Среди спектра нежелательных явлений наиболее часто фи гурируют пороки развития, респираторные и гемато логические осложнения [20,21].…”

Section: Introductionunclassified

Combination of lymphoproliferative diseases and pregnancy

Chernyshova,

Chernyakov,

Popova

et al. 2023

Onkogematologiâ

View full text Add to dashboard Cite

The article presents an analysis of the current state of the problem of the combination of lymphoproliferative diseases associated with pregnancy. Analysis of literature sources has shown that despite the seemingly obvious unfavorable relationship between pregnancy and lymphoproliferative diseases, most studies demonstrate a favorable prognosis regarding the prognosis and outcome of this oncological pathology in combination with pregnancy. The Research Institute of Oncology of the Tomsk SRI has sufficient experience in the treatment of this pathology, including on the background of pregnancy. We have presented two clinical cases in which successful treatment of lymphoproliferative processes in pregnant women has been demonstrated.

show abstract